The Potential of T Cell Immunotherapy to Eradicate Cancer

The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno’s technologies genetically engineer a patient’s own T cells to recognize and attack cancer cells. These cell-based therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. We use two different technologies to target cancer cells and activate T cells, CARs and TCRs.

Tumor cells being killed by genetically engineered T cells

From the Jensen Lab, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute.

Scientific Platform

Cell-based therapies

Our goal is to revolutionize medicine through cell-based therapies. We believe genetically-engineered T cells have the potential to meaningfully improve survival and quality of life for cancer patients.

CAR Technology

Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptor (CAR) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins.

TCR Technology

T Cell Receptors (TCRs)

High-affinity TCR technology provides the T cells with a specific T cell receptor that recognizes protein fragments derived from either intracellular or extracellular proteins.